Table 3.
GIS | Mosapride citrate SR group | Mosapride citrate CR group | Difference [95% CI]a | P-value |
---|---|---|---|---|
PPS | n = 51 | n = 49 | ||
Baseline | 13.55 ± 5.21 | 13.84 ± 5.32 | 0.721c | |
Week 4 | 3.51 ± 3.85 | 2.98 ± 3.11 | ||
Changeb | –10.04 ± 4.45 | –10.86 ± 5.53 | 0.82 [–1.17, 2.81] | 0.643c |
In group P-value | < 0.001d | < 0.001d | ||
FAS | n = 57 | n = 57 | ||
Baseline | 13.55 ± 5.00 | 14.07 ± 5.58 | 0.541c | |
Week 4 | 3.49 ± 3.82 | 3.70 ± 5.22 | ||
Change | –9.86 ± 4.48 | –10.37 ± 6.23 | 0.51 [–1.51, 2.52] | 0.820c |
In group P-value | < 0.001d | < 0.001d |
GIS, gastrointestinal symptom scores; PPS, per-protocol set; FAS, full analysis set.
aInter-group Difference [95% CI] = mosapride citrate SR-mosapride citrate CR 95% CI based on t test.
bChanges in score related to symptoms (week 4-baseline).
cWilcoxon rank sum test.
dWilcoxon signed rank test.